Nordic nanovector_PhII_CD37_mAb_radionuclide_FL (Non-Hodgkin Lymphoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how different amounts of the study drug work on follicular lymphoma.

What is the Condition Being Studied?

Relapsed/Refractory Follicular Lymphoma

Who Can Participate in the Study?

Adults who:
-Have relapsed Follicular Lymphoma and have received 2 or more chemotherapy or immunotherapy based regimens.

Age Group

What is Involved?

If you choose to be in this study:
-You will be randomly assigned (like flipping a coin) to get either dose A or does B of the study drug Betalutin. The only difference in the groups is the amount of the study drug given.
-Receive one single dose of study drug as an injection into a vein
-Give a small blood sample once a week for 12 weeks
-Follow-up visits 3 to 6 months for up to 5 years
-CT/PET scans at some follow-up visits

Study Details

Full Title
A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide- conjugate for treatment of relapsed non-Hodgkin lymphoma.
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00101230
NCT: NCT01796171
Phase I/II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center